Cassava SciencesSAVA
SAVA
About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Employees: 30
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
71% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $1.93M
3.46% less ownership
Funds ownership: 36.19% [Q4 2024] → 32.73% (-3.46%) [Q1 2025]
15% less funds holding
Funds holding: 137 [Q4 2024] → 117 (-20) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 42
38% less capital invested
Capital invested by funds: $41.1M [Q4 2024] → $25.6M (-$15.5M) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 36
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
2%
downside
Avg. target
$2
2%
downside
High target
$2
2%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino | 2%downside $2 | Neutral Reiterated | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible for leading Cassava's research and development efforts.
Neutral
GlobeNewsWire
1 month ago
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer.
Positive
Zacks Investment Research
2 months ago
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Zacks Investment Research
2 months ago
Is the Future Bleak for SAVA Stock Following Another Setback?
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
Negative
Reuters
2 months ago
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam.
Negative
Zacks Investment Research
2 months ago
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Negative
Benzinga
2 months ago
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences Inc. SAVA on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
Neutral
GlobeNewsWire
2 months ago
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD.
Positive
Zacks Investment Research
3 months ago
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
3 months ago
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update.
Charts implemented using Lightweight Charts™